{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:27Z","timestamp":1786649367777,"version":"build-2736575974"},"reference-count":187,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness and fatigue due to autoantibodies impairing neuromuscular transmission. With a global prevalence of 40\u2013180 per million, Taiwan has seen a rise in MG cases from 4476 in 2013 to 5752 in 2019, with generalized MG (GMG) prevalence increasing significantly, whereas GMG patients incur substantially higher medical costs and resource utilization compared to non-MG patients. To standardize MG management, the Society formed an expert committee of 37 MG specialists and a patient representative, tasked with developing evidence-based guidelines. The committee, organized into 11 thematic subgroups, conducted a systematic review of literature from 2015 to 2024 and employed a Modified Delphi method to achieve consensus on clinical guidance statements. Recommendations cover diagnosis (e.g., antibody testing and electrophysiological tests), treatment (e.g. thymectomy, steroids, and novel biologics), and management of specific MG subtypes, including ocular, early- and late-onset, muscle-specific tyrosine kinase-related, and refractory MG, as well as myasthenic crisis and neonatal MG. The guidelines emphasize early diagnosis, integrated management of comorbidities, and long-term care strategies, including patient support and tailored exercise programs. These consensus statements aim to enhance care quality, improve patient outcomes, and guide future research and pharmaceutical development in Taiwan\u2019s medical community.<\/jats:p>","DOI":"10.4103\/ant.ant-d-25-00063","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T21:00:08Z","timestamp":1777150808000},"page":"59-69","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Taiwan Clinical Practice Guidelines for Myasthenia Gravis"],"prefix":"10.4103","volume":"35","author":[{"given":"Hsu-Ling","family":"Yeh","sequence":"first","affiliation":[{"name":"Department of Neurology, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Cheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fu Jen Catholic University Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Bang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hualien Tzu Chi Hospital, Hualien, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Han","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Sun","family":"Ro","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Yu","family":"Tiong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Jen","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chung","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Peripheral Neurology, Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ning","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lang","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thy-Sheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cheng Kung University Hospital, Tainan, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chu","family":"Liao","sequence":"additional","affiliation":[{"name":"Division of Peripheral Neurology, Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chih","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Hsuan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ping","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ting","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cheng Kung University Hospital, Tainan, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Cherng","family":"Guo","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Genetic Disorders, Department of Neurology, China Medical University Hospital, Taichung, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Mei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsing","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chao","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Che","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Department of Pediatrics, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Jun","family":"Chou","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Department of Pediatrics, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Ting","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Department of Pediatrics, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Shu","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Brain Function and Epilepsy, Department of Neurology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon-Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Lung","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Neurology, New Taipei City Municipal Tucheng Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Wen","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Horng","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hou-Chang","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Taipei Medical University\u2013Shuang Ho Hospital, New Taipei, Taiwan"},{"name":"Taiwan Neuroimmunology Medical Society"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"R1-20260427","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20260427","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1007\/s00415-022-10986-3","article-title":"Bedside and laboratory diagnostic testing in myasthenia","volume":"269","author":"Yoganathan","year":"2022","journal-title":"J Neurol"},{"key":"R3-20260427","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"R4-20260427","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40120-024-00619-4","article-title":"Epidemiology, patient characteristics, and treatment patterns of myasthenia gravis in Taiwan: A population-based study","volume":"13","author":"Tsai","year":"2024","journal-title":"Neurol Ther"},{"key":"R5-20260427","doi-asserted-by":"crossref","first-page":"1203679","DOI":"10.3389\/fneur.2023.1203679","article-title":"The growing burden of generalized myasthenia gravis: A population-based retrospective cohort study in Taiwan","volume":"14","author":"Herr","year":"2023","journal-title":"Front Neurol"},{"key":"R6-20260427","doi-asserted-by":"crossref","first-page":"1216595","DOI":"10.3389\/fneur.2023.1216595","article-title":"Healthcare resource utilization and costs associated with generalized myasthenia gravis: A retrospective matched cohort study using the National Health Insurance Research database in Taiwan","volume":"14","author":"Shen","year":"2023","journal-title":"Front Neurol"},{"key":"R8-20260427","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mus.27500","article-title":"Positive acetylcholine receptor antibody in nonmyasthenic patients","volume":"65","author":"Sun","year":"2022","journal-title":"Muscle Nerve"},{"key":"R9-20260427","doi-asserted-by":"crossref","first-page":"e114060","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PLoS One"},{"key":"R10-20260427","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","article-title":"Antibody profile may predict outcome in ocular myasthenia gravis","volume":"118","author":"Galassi","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"R11-20260427","first-page":"120","article-title":"Electrophysiological studies in patients with seropositive\/seronegative myasthenia gravis","volume":"20","author":"Vahabi","year":"2021","journal-title":"Curr J Neurol"},{"key":"R12-20260427","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/mus.25500","article-title":"Single-fiber EMG with concentric electrodes in Lambert-Eaton myasthenia","volume":"56","author":"Guan","year":"2017","journal-title":"Muscle Nerve"},{"key":"R13-20260427","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mus.24745","article-title":"Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature","volume":"52","author":"Chiou-Tan","year":"2015","journal-title":"Muscle Nerve"},{"key":"R14-20260427","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.25539","article-title":"Electrophysiological testing is correlated with myasthenia gravis severity","volume":"56","author":"Abraham","year":"2017","journal-title":"Muscle Nerve"},{"key":"R15-20260427","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.4103\/ijo.IJO_2015_21","article-title":"Diagnostic accuracy and clinical utility of bed side tests versus laboratory tests in the diagnosis of ocular myasthenia","volume":"70","author":"Sivakumar","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R16-20260427","doi-asserted-by":"crossref","first-page":"e1800","DOI":"10.1212\/WNL.0000000000010619","article-title":"Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis","volume":"95","author":"Giannoccaro","year":"2020","journal-title":"Neurology"},{"key":"R17-20260427","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00415-019-09631-3","article-title":"Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation","volume":"267","author":"Giannoccaro","year":"2020","journal-title":"J Neurol"},{"key":"R18-20260427","first-page":"93","article-title":"A comparative study of single fiber electromyography and repetitive nerve stimulation in consecutive patients with myasthenia gravis","volume":"47","author":"Srivastava","year":"2007","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"R19-20260427","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1002\/brb3.537","article-title":"Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course","volume":"6","author":"Kubiszewska","year":"2016","journal-title":"Brain Behav"},{"key":"R20-20260427","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1468-1331.2007.01978.x","article-title":"Clinical features of patients with myasthenia gravis associated with autoimmune diseases","volume":"14","author":"Kanazawa","year":"2007","journal-title":"Eur J Neurol"},{"key":"R21-20260427","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/ene.12169","article-title":"Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis","volume":"20","author":"Nakata","year":"2013","journal-title":"Eur J Neurol"},{"key":"R22-20260427","doi-asserted-by":"crossref","first-page":"102368","DOI":"10.1016\/j.autrev.2019.102368","article-title":"Thyroid disorders in patients with myasthenia gravis: A systematic review and meta-analysis","volume":"18","author":"Song","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R23-20260427","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40618-018-0945-6","article-title":"Usefulness of TSH receptor antibodies as biomarkers for Graves\u2019 ophthalmopathy: A systematic review","volume":"41","author":"Seo","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"R24-20260427","doi-asserted-by":"crossref","first-page":"17562864231213240","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"R25-20260427","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"R26-20260427","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"R27-20260427","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1212\/WNL.0000000000010031","article-title":"Minimal manifestation status and prednisone withdrawal in the MGTX trial","volume":"95","author":"Lee","year":"2020","journal-title":"Neurology"},{"key":"R28-20260427","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/13543784.2021.2010704","article-title":"Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis","volume":"30","author":"Chen","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"R29-20260427","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/00207454.2016.1257993","article-title":"Prognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia","volume":"127","author":"Yang","year":"2017","journal-title":"Int J Neurosci"},{"key":"R30-20260427","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.21037\/atm.2019.06.65","article-title":"MGTX extension study longitudinally favors early thymectomy in non-thymomatous young-adult patients with AChR antibody-positive myasthenia gravis","volume":"7","author":"Akaishi","year":"2019","journal-title":"Ann Transl Med"},{"key":"R31-20260427","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13023-021-01860-y","article-title":"Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: Systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R32-20260427","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/ejcts\/ezab253","article-title":"Robotic thymectomy for thymoma in patients with myasthenia gravis: Neurological and oncological outcomes","volume":"60","author":"Romano","year":"2021","journal-title":"Eur J Cardiothorac Surg"},{"key":"R33-20260427","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2019.02.016","article-title":"Results of robotic thymectomy performed in myasthenia gravis patients older than 60 years at onset","volume":"108","author":"Li","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R34-20260427","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000511300","article-title":"Case series: Clinical impact of plasmapheresis and thymectomy on early-onset myasthenia gravis","volume":"13","author":"Siahaan","year":"2021","journal-title":"Case Rep Neurol"},{"key":"R35-20260427","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","article-title":"A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"Alipour-Faz","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"R36-20260427","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14712590802588831","article-title":"A comparison of long-term post-thymectomy outcome of anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis","volume":"9","author":"Ponseti","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"R37-20260427","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve"},{"key":"R38-20260427","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"R39-20260427","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"R40-20260427","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"R41-20260427","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"key":"R42-20260427","doi-asserted-by":"crossref","first-page":"1756286419876521","DOI":"10.1177\/1756286419876521","article-title":"Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: A systematic review and meta-analysis","volume":"12","author":"Li","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"R43-20260427","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00415-008-0718-9","article-title":"Mycophenolate mofetil for ocular myasthenia","volume":"255","author":"Chan","year":"2008","journal-title":"J Neurol"},{"key":"R44-20260427","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/CND.0b013e31821c5634","article-title":"Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: Clinical features and therapeutic response","volume":"13","author":"Mittal","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"R45-20260427","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: Response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R46-20260427","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10384-020-00770-z","article-title":"Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis","volume":"64","author":"Isshiki","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"R47-20260427","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1016\/j.nmd.2017.06.464","article-title":"Tacrolimus treatment in patients with long-standing ocular myasthenia gravis","volume":"27","author":"Oh","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"R48-20260427","first-page":"CD002828","article-title":"Corticosteroids for myasthenia gravis","volume":"2005","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R49-20260427","doi-asserted-by":"crossref","first-page":"1259484","DOI":"10.3389\/fneur.2023.1259484","article-title":"Effectiveness of early glucocorticoids in myasthenia gravis: A retrospective cohort study","volume":"14","author":"Zhen","year":"2023","journal-title":"Front Neurol"},{"key":"R50-20260427","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"R51-20260427","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000114612","article-title":"Long-term treatment of myasthenia gravis with alternate-day prednisone. Report on 15 patients","volume":"12","author":"Pinelli","year":"1974","journal-title":"Eur Neurol"},{"key":"R52-20260427","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: What is the evidence? A systematic review","volume":"268","author":"Lotan","year":"2021","journal-title":"J Neurol"},{"key":"R53-20260427","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J Clin Neurosci"},{"key":"R54-20260427","first-page":"123","article-title":"Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis","volume":"15","author":"Cosi","year":"1993","journal-title":"Acta Neurol (Napoli)"},{"key":"R55-20260427","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","article-title":"Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis","volume":"150","author":"Bromberg","year":"1997","journal-title":"J Neurol Sci"},{"key":"R56-20260427","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","article-title":"A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis","volume":"56","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R57-20260427","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"R58-20260427","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"R59-20260427","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"R60-20260427","doi-asserted-by":"crossref","first-page":"e1426","DOI":"10.1212\/WNL.0000000000010209","article-title":"Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis","volume":"95","author":"Tomschik","year":"2020","journal-title":"Neurology"},{"key":"R61-20260427","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/cen.13537","article-title":"Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment","volume":"88","author":"Lv","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R62-20260427","doi-asserted-by":"crossref","first-page":"16","DOI":"10.17712\/nsj.2022.1.20210096","article-title":"Clinical delineation of myasthenia gravis in the Kingdom of Bahrain","volume":"27","author":"Binfalah","year":"2022","journal-title":"Neurosciences (Riyadh)"},{"key":"R63-20260427","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s42466-020-00091-z","article-title":"Outcome measures and treatment effectiveness in late onset myasthenia gravis","volume":"2","author":"Pasqualin","year":"2020","journal-title":"Neurol Res Pract"},{"key":"R64-20260427","doi-asserted-by":"crossref","first-page":"843523","DOI":"10.3389\/fneur.2022.843523","article-title":"Efficacy and safety of tacrolimus therapy for a single Chinese cohort with very-late-onset myasthenia gravis","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Neurol"},{"key":"R65-20260427","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nmd.2022.12.004","article-title":"A very late onset AChR and MuSK double positive myasthenia gravis: A case description and literature review","volume":"33","author":"Pugliese","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"R66-20260427","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s13760-020-01290-w","article-title":"Very late onset of myasthenia gravis: case report and brief review of the literature","volume":"120","author":"Oliveira","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"R67-20260427","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13760-019-01252-x","article-title":"Late-onset generalized myasthenia gravis: Clinical features, treatment, and outcome","volume":"120","author":"Yildiz Celik","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"R68-20260427","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"R69-20260427","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mus.26876","article-title":"Rituximab in late-onset myasthenia gravis is safe and effective","volume":"62","author":"Sahai","year":"2020","journal-title":"Muscle Nerve"},{"key":"R70-20260427","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"R71-20260427","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.nmd.2023.02.013","article-title":"Clinical characteristics and prognosis of very late-onset myasthenia gravis in China","volume":"33","author":"Tang","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"R72-20260427","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/JCM.S29601","article-title":"Treatment of myasthenia gravis in patients with elderly onset at advanced age","volume":"6","author":"Nishikawa","year":"2015","journal-title":"Jpn Clin Med"},{"key":"R73-20260427","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12883-022-02593-6","article-title":"Spotlight on MuSK positive myasthenia gravis: Clinical characteristics, treatment and outcomes","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Neurol"},{"key":"R74-20260427","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000479228","article-title":"Prompt response to prednisone predicts benign course in MuSK-MG","volume":"78","author":"Gungor-Tuncer","year":"2017","journal-title":"Eur Neurol"},{"key":"R75-20260427","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: A U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"R76-20260427","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK-versus anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"R77-20260427","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R78-20260427","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis","volume":"5","author":"Cort\u00e9s-Vicente","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"R79-20260427","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"R80-20260427","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","article-title":"Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients","volume":"84","author":"Keung","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R81-20260427","doi-asserted-by":"crossref","first-page":"116690","DOI":"10.1016\/j.jns.2020.116690","article-title":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: A single-center retrospective study","volume":"411","author":"Litchman","year":"2020","journal-title":"J Neurol Sci"},{"key":"R82-20260427","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"R83-20260427","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/NDT.S358851","article-title":"Efficacy and safety of low-dose rituximab in anti-MuSK myasthenia gravis patients: A retrospective study","volume":"18","author":"Meng","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R84-20260427","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"R85-20260427","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"R86-20260427","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jca.21377","article-title":"Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients","volume":"30","author":"Yamada","year":"2015","journal-title":"J Clin Apher"},{"key":"R87-20260427","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2169\/internalmedicine.9466-17","article-title":"Anti-MuSK antibody-positive myasthenia gravis successfully treated with outpatient periodic weekly blood purification therapy","volume":"57","author":"Deguchi","year":"2018","journal-title":"Intern Med"},{"key":"R88-20260427","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur J Neurol"},{"key":"R89-20260427","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/mus.25591","article-title":"Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis","volume":"56","author":"Li","year":"2017","journal-title":"Muscle Nerve"},{"key":"R90-20260427","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/acn3.51492","article-title":"Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome","volume":"9","author":"Cort\u00e9s-Vicente","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"R91-20260427","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.nmd.2019.06.002","article-title":"Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis","volume":"29","author":"Roda","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"R92-20260427","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s42466-019-0023-3","article-title":"SOP myasthenic crisis","volume":"1","author":"Stetefeld","year":"2019","journal-title":"Neurol Res Pract"},{"key":"R93-20260427","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1590\/S0004-282X2004000300003","article-title":"Plasmapheresis in the treatment of myasthenia gravis: Retrospective study of 26 patients","volume":"62","author":"Carandina-Maffeis","year":"2004","journal-title":"Arq Neuropsiquiatr"},{"key":"R94-20260427","first-page":"129","article-title":"Clinical profile and outcome of myasthenic crisis in Central Taiwan","volume":"25","author":"Wong","year":"2016","journal-title":"Acta Neurol Taiwan"},{"key":"R95-20260427","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00003246-199707000-00027","article-title":"Therapy of myasthenic crisis","volume":"25","author":"Berrouschot","year":"1997","journal-title":"Crit Care Med"},{"key":"R96-20260427","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1034\/j.1600-0404.2001.104002078.x","article-title":"Double filtration plasmapheresis in the treatment of myasthenic crisis \u2013 Analysis of prognostic factors and efficacy","volume":"104","author":"Yeh","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"R97-20260427","doi-asserted-by":"crossref","first-page":"662856","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic plasma exchange in myasthenia gravis: A systematic literature review and meta-analysis of comparative evidence","volume":"12","author":"Ipe","year":"2021","journal-title":"Front Neurol"},{"key":"R98-20260427","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.pjnns.2016.07.005","article-title":"Improvement of quality of life after therapeutic plasma exchange in patients with myasthenic crisis","volume":"50","author":"Rozmilowska","year":"2016","journal-title":"Neurol Neurochir Pol"},{"key":"R99-20260427","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/acn3.50901","article-title":"Clinical outcome measures following plasma exchange for MG exacerbation","volume":"6","author":"Raja","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"R100-20260427","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1196\/annals.1405.001","article-title":"Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin","volume":"1132","author":"Gajdos","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R101-20260427","first-page":"CD002277","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"12","author":"Gajdos","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R102-20260427","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"R103-20260427","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1196\/annals.1405.038","article-title":"IVIG treatment for myasthenia gravis: Effectiveness, limitations, and novel therapeutic strategies","volume":"1132","author":"Zinman","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R104-20260427","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","article-title":"Immunoglobulin treatment in refractory myasthenia gravis","volume":"23","author":"Achiron","year":"2000","journal-title":"Muscle Nerve"},{"key":"R105-20260427","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"R106-20260427","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"R107-20260427","doi-asserted-by":"crossref","first-page":"109058","DOI":"10.1016\/j.clim.2022.109058","article-title":"Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study","volume":"241","author":"Wang","year":"2022","journal-title":"Clin Immunol"},{"key":"R108-20260427","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"R109-20260427","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.22139","article-title":"Comparative analysis of therapeutic options used for myasthenia gravis","volume":"68","author":"Mandawat","year":"2010","journal-title":"Ann Neurol"},{"key":"R110-20260427","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/nsn.nsn_175_22","article-title":"High-dose steroids versus standard treatment for myasthenic crisis","volume":"40","author":"Figuera Rabor","year":"2023","journal-title":"Neurol Sci Neurophysio"},{"key":"R111-20260427","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and lambert \u2013 Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"R112-20260427","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"R113-20260427","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4103\/0028-3886.289001","article-title":"Noninvasive ventilation in myasthenia gravis","volume":"68","author":"Misra","year":"2020","journal-title":"Neurol India"},{"key":"R114-20260427","first-page":"15","article-title":"Cardiac disorders worsen the final outcome in myasthenic crisis undergoing non-invasive mechanical ventilation: A retrospective 20-year study from a single center","volume":"41","author":"Iori","year":"2022","journal-title":"Acta Myol"},{"key":"R115-20260427","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.880150616","article-title":"Diagnostic sensitivity of the laboratory tests in myasthenia gravis","volume":"15","author":"Oh","year":"1992","journal-title":"Muscle Nerve"},{"key":"R116-20260427","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mus.21191","article-title":"Racial differences in myasthenia gravis in Alabama","volume":"39","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"R117-20260427","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/mus.26390","article-title":"Repetitive nerve stimulation test in myasthenic crisis","volume":"59","author":"Oh","year":"2019","journal-title":"Muscle Nerve"},{"key":"R118-20260427","doi-asserted-by":"crossref","first-page":"767961","DOI":"10.3389\/fneur.2021.767961","article-title":"Patients with myasthenia gravis with acute onset of dyspnea: Predictors of progression to myasthenic crisis and prognosis","volume":"12","author":"Huang","year":"2021","journal-title":"Front Neurol"},{"key":"R119-20260427","first-page":"524","article-title":"Isolated COVID-19 infection precipitates myasthenia gravis crisis: A case report","volume":"4","author":"Moschella","year":"2020","journal-title":"Clin Pract Cases Emerg Med"},{"key":"R120-20260427","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13023-022-02205-z","article-title":"Risk factors for pregnancy-related clinical outcome in myasthenia gravis: A systemic review and meta-analysis","volume":"17","author":"Su","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"R121-20260427","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1753495X211041899","article-title":"Myasthenia gravis in pregnancy: Systematic review and case series","volume":"15","author":"Banner","year":"2022","journal-title":"Obstet Med"},{"key":"R122-20260427","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nmd.2017.01.021","article-title":"Clinical follow-up of pregnancy in myasthenia gravis patients","volume":"27","author":"Ducci","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"R123-20260427","first-page":"141","article-title":"Outcome of myasthenia gravis mothers and their infants","volume":"48","author":"Cheng","year":"2007","journal-title":"Acta Paediatr Taiwan"},{"key":"R124-20260427","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1468-1331.2006.01538.x","article-title":"Myasthenia gravis in pregnancy and birth: Identifying risk factors, optimising care","volume":"14","author":"Hoff","year":"2007","journal-title":"Eur J Neurol"},{"key":"R125-20260427","doi-asserted-by":"crossref","first-page":"e16100","DOI":"10.1111\/ene.16100","article-title":"Pregnancy outcomes for women with myasthenia gravis and their newborns: A nationwide register-based cohort study","volume":"31","author":"O\u2019Connor","year":"2024","journal-title":"Eur J Neurol"},{"key":"R126-20260427","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1515\/jpm-2020-0163","article-title":"Maternal and neonatal outcomes among pregnant women with myasthenia gravis","volume":"48","author":"Nicholls-Dempsey","year":"2020","journal-title":"J Perinat Med"},{"key":"R127-20260427","first-page":"767","article-title":"Myasthenia gravis and pregnancy: Toronto specialty center experience","volume":"48","author":"Alharbi","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"R128-20260427","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/mus.28021","article-title":"Pregnancy planning may impact maternal and neonatal outcomes in people with myasthenia gravis","volume":"69","author":"Anabusi","year":"2024","journal-title":"Muscle Nerve"},{"key":"R129-20260427","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/15513815.2016.1164773","article-title":"Neonatal outcome in pregnancies with autoimmune myasthenia gravis","volume":"35","author":"Jovandaric","year":"2016","journal-title":"Fetal Pediatr Pathol"},{"key":"R130-20260427","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1038\/s41372-021-00970-6","article-title":"Transient neonatal myasthenia gravis: Refining risk estimate for infants born to women with myasthenia gravis","volume":"41","author":"Kochhar","year":"2021","journal-title":"J Perinatol"},{"key":"R131-20260427","doi-asserted-by":"crossref","first-page":"e2368","DOI":"10.1212\/WNL.0000000000200288","article-title":"Rituximab therapy in the treatment of juvenile myasthenia gravis: The French experience","volume":"98","author":"Molimard","year":"2022","journal-title":"Neurology"},{"key":"R132-20260427","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","article-title":"Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone","volume":"77","author":"Liu","year":"2017","journal-title":"Pediatr Neurol"},{"key":"R133-20260427","doi-asserted-by":"crossref","first-page":"1223322","DOI":"10.3389\/fimmu.2023.1223322","article-title":"Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"R134-20260427","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3109\/08916934.2015.1031890","article-title":"Poly-autoimmunity in patients with myasthenia gravis: A single-center experience","volume":"48","author":"Evoli","year":"2015","journal-title":"Autoimmunity"},{"key":"R135-20260427","doi-asserted-by":"crossref","first-page":"790941","DOI":"10.3389\/fneur.2021.790941","article-title":"Comorbid autoimmune diseases in patients with myasthenia gravis: A retrospective cross-sectional study of a Chinese cohort","volume":"12","author":"Shi","year":"2021","journal-title":"Front Neurol"},{"key":"R136-20260427","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: A Swedish population-based study","volume":"277","author":"Fang","year":"2015","journal-title":"J Intern Med"},{"key":"R137-20260427","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s10072-023-07163-3","article-title":"Myasthenia gravis and five autoimmune diseases: A bidirectional Mendelian randomization study","volume":"45","author":"Li","year":"2024","journal-title":"Neurol Sci"},{"key":"R138-20260427","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1097\/MD.0000000000000835","article-title":"Higher risk of myasthenia gravis in patients with thyroid and allergic diseases: A national population-based study","volume":"94","author":"Yeh","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R139-20260427","doi-asserted-by":"crossref","first-page":"109810","DOI":"10.1016\/j.clim.2023.109810","article-title":"Association between systemic lupus erythematosus and myasthenia gravis: A population-based national study","volume":"260","author":"Igoe","year":"2024","journal-title":"Clin Immunol"},{"key":"R140-20260427","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1759-7714.14723","article-title":"Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort","volume":"14","author":"Tian","year":"2023","journal-title":"Thorac Cancer"},{"key":"R141-20260427","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s13304-023-01568-7","article-title":"Combined effect of thymectomy on myasthenia gravis in patients with concomitant auto-immune diseases: A 22-year single-center experience","volume":"75","author":"Liu","year":"2023","journal-title":"Updates Surg"},{"key":"R142-20260427","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","article-title":"A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis","volume":"22","author":"Harris","year":"2022","journal-title":"BMC Neurol"},{"key":"R143-20260427","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4103\/aian.AIAN_197_19","article-title":"Comorbidities and long-term outcomes in a cohort with myasthenic crisis: Experiences from a tertiary care center","volume":"22","author":"Sivadasan","year":"2019","journal-title":"Ann Indian Acad Neurol"},{"key":"R144-20260427","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.semarthrit.2018.05.004","article-title":"Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: A case series and literature review","volume":"48","author":"Huang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R145-20260427","first-page":"Doc12","article-title":"Refractory myasthenia gravis \u2013 Clinical profile, comorbidities and response to rituximab","volume":"14","author":"Sudulagunta","year":"2016","journal-title":"Ger Med Sci"},{"key":"R146-20260427","first-page":"e19416","article-title":"Rituximab in the management of refractory myasthenia gravis and variability of its efficacy in anti-MuSK positive and anti-AChR positive myasthenia gravis","volume":"13","author":"Bastakoti","year":"2021","journal-title":"Cureus"},{"key":"R147-20260427","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"R148-20260427","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: Extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"R149-20260427","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: A prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"R150-20260427","first-page":"e13226","article-title":"Rituximab in Refractory myasthenia gravis: Experience in a single healthcare center in mexico","volume":"13","author":"L\u00f3pez-Hern\u00e1ndez","year":"2021","journal-title":"Cureus"},{"key":"R151-20260427","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol"},{"key":"R152-20260427","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/CND.0000000000000420","article-title":"Long-term remission with low-dose rituximab in myasthenia gravis: A retrospective study","volume":"24","author":"Castiglione","year":"2022","journal-title":"J Clin Neuromuscul Dis"},{"key":"R153-20260427","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pediatrneurol.2020.07.002","article-title":"Rituximab as adjunct maintenance therapy for refractory juvenile myasthenia gravis","volume":"111","author":"Zingariello","year":"2020","journal-title":"Pediatr Neurol"},{"key":"R154-20260427","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1159\/000510396","article-title":"Therapeutic and immunoregulatory effects of tacrolimus in patients with refractory generalized myasthenia gravis","volume":"83","author":"Wu","year":"2020","journal-title":"Eur Neurol"},{"key":"R155-20260427","doi-asserted-by":"crossref","first-page":"577955","DOI":"10.1016\/j.jneuroim.2022.577955","article-title":"Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis","volume":"372","author":"Wu","year":"2022","journal-title":"J Neuroimmunol"},{"key":"R156-20260427","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jns.2006.03.010","article-title":"Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis","volume":"247","author":"Tada","year":"2006","journal-title":"J Neurol Sci"},{"key":"R157-20260427","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"R158-20260427","doi-asserted-by":"crossref","first-page":"556104","DOI":"10.3389\/fneur.2020.556104","article-title":"Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study","volume":"11","author":"Nowak","year":"2020","journal-title":"Front Neurol"},{"key":"R159-20260427","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/mus.27656","article-title":"Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Muscle Nerve"},{"key":"R160-20260427","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JND-200584","article-title":"Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"8","author":"Katyal","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"R161-20260427","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JND-190464","article-title":"Retrospective analysis of eculizumab in patients with acetylcholine receptor antibody-negative myasthenia gravis: A case series","volume":"7","author":"Datta","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"R162-20260427","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"R163-20260427","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: Results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacc\u00e0","year":"2023","journal-title":"J Neurol"},{"key":"R164-20260427","doi-asserted-by":"crossref","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"R165-20260427","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Results from the phase 3 champion MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J Neurol"},{"key":"R166-20260427","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"R167-20260427","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"R168-20260427","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0","year":"2023","journal-title":"Eur J Neurol"},{"key":"R169-20260427","doi-asserted-by":"crossref","first-page":"1280226","DOI":"10.3389\/fimmu.2023.1280226","article-title":"Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: A Bayesian network analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"R170-20260427","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jocn.2020.06.023","article-title":"Fatigue, self-efficacy and psychiatric symptoms influence the quality of life in patients with myasthenia gravis in Tianjin, China","volume":"79","author":"Fan","year":"2020","journal-title":"J Clin Neurosci"},{"key":"R171-20260427","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s13760-018-0915-y","article-title":"Quality of life in patients with MuSK positive myasthenia gravis","volume":"118","author":"Stankovic","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"R172-20260427","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: Taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"R173-20260427","first-page":"595","article-title":"Disease Burden of Myasthenia Gravis","volume":"28","author":"Chiu","year":"2024","journal-title":"Formosan Journal of Medicine"},{"key":"R174-20260427","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/medicina60010056","article-title":"Depression: A contributing factor to the clinical course in myasthenia gravis patients","volume":"60","author":"Mihalache","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R175-20260427","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12883-020-01802-4","article-title":"Prospective study of stress, depression and personality in myasthenia gravis relapses","volume":"20","author":"Bogdan","year":"2020","journal-title":"BMC Neurol"},{"key":"R176-20260427","first-page":"707","article-title":"Stressor, Social Support and Resilience in Patients with Myasthenia Gravis","volume":"25","author":"Wang","year":"2021","journal-title":"Formosan Journal of Medicine"},{"key":"R177-20260427","first-page":"21","article-title":"The Effect of Positive Mental Health BMI (Befriend-Mindfulness-Identity) by Group Counseling on Patients with Myasthenia Gravis","volume":"26","author":"Yeh","year":"2022","journal-title":"Formosan Journal of Medicine"},{"key":"R178-20260427","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000513668","article-title":"Rest or 30-Min walk as exercise intervention (RESTOREX) in myasthenia gravis: A randomized controlled trial","volume":"84","author":"Misra","year":"2021","journal-title":"Eur Neurol"},{"key":"R179-20260427","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/JND-210722","article-title":"Physical activity and sedentary behaviour in people with myasthenia gravis: A cross-sectional study","volume":"9","author":"Alsop","year":"2022","journal-title":"J Neuromuscul Dis"},{"key":"R180-20260427","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mus.25552","article-title":"Exercise in myasthenia gravis: A feasibility study of aerobic and resistance training","volume":"56","author":"Rahbek","year":"2017","journal-title":"Muscle Nerve"},{"key":"R181-20260427","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.3390\/jcm10174031","article-title":"Changes in physical fitness and body composition associated with physical exercise in patients with myasthenia gravis: A longitudinal prospective study","volume":"10","author":"Chang","year":"2021","journal-title":"J Clin Med"},{"key":"R182-20260427","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/mus.25493","article-title":"Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: A pilot study","volume":"56","author":"Westerberg","year":"2017","journal-title":"Muscle Nerve"},{"key":"R183-20260427","doi-asserted-by":"crossref","first-page":"e11510","DOI":"10.1097\/MD.0000000000011510","article-title":"The impact of physical exercise on neuromuscular function in myasthenia gravis patients: A single-subject design study","volume":"97","author":"Westerberg","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R184-20260427","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.nmd.2021.05.002","article-title":"Home-based exercise in autoimmune myasthenia gravis: A randomized controlled trial","volume":"31","author":"Birnbaum","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"R185-20260427","doi-asserted-by":"crossref","first-page":"8442","DOI":"10.1080\/09638288.2021.2022221","article-title":"The effects of spinal stabilization exercises in patients with myasthenia gravis: A randomized crossover study","volume":"44","author":"Ceren","year":"2022","journal-title":"Disabil Rehabil"},{"key":"R186-20260427","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mus.24054","article-title":"Effects of balance strategy training in myasthenia gravis: A case study series","volume":"49","author":"Wong","year":"2014","journal-title":"Muscle Nerve"},{"key":"R187-20260427","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.rmed.2018.09.001","article-title":"Effects of long-term respiratory muscle endurance training on respiratory and functional outcomes in patients with myasthenia gravis","volume":"144","author":"Freitag","year":"2018","journal-title":"Respir Med"},{"key":"R188-20260427","doi-asserted-by":"crossref","first-page":"2923907","DOI":"10.1155\/2020\/2923907","article-title":"Respiratory muscle training improves functional outcomes and reduces fatigue in patients with myasthenia gravis: A single-center hospital-based prospective study","volume":"2020","author":"Hsu","year":"2020","journal-title":"Biomed Res Int"}],"container-title":["Acta Neurologica Taiwanica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ant.ANT-D-25-00063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:53:10Z","timestamp":1786647190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ant.ANT-D-25-00063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":187,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ant.ant-d-25-00063","relation":{},"ISSN":["1028-768X","3050-9173"],"issn-type":[{"value":"1028-768X","type":"print"},{"value":"3050-9173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-06-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}